PS, propensity score matching. All data are means (SD) or number of participants (%).
| Baricitinib group (n = 83) | PS control group (n = 83) | |
| Age | 74.0 (12.5) | 74.1 (13.6) |
| Male sex | 43 (51.8) | 42 (50.6) |
| Coexisting conditions | ||
| Hypertension | 50 (60.2) | 53 (63.9) |
| Cardiovascular disease | 27 (32.5) | 21 (25.3) |
| Solid cancer | 8 (9.6) | 10 (12.0) |
| Diabetes | 28 (33.7) | 22 (26.5) |
| COPD | 12 (14.5) | 12 (14.5) |
| Chronic kidney failure | 7 (8.4) | 7 (8.4) |
| Charlson comorbidity index | 2.7 (2.3) | 2.8 (2.7) |
| Medications at baseline | ||
| ACE inhibitor or ARB | 33 (39.8) | 35 (42.2) |
| Baseline PaO2/FiO2 | 268 (101) | 266 (86) |
| Baseline laboratory tests | ||
| C-reactive protein (mg/liter) | 86.0 (100.6) | 82.2 (123.9) |
| Lymphocyte count (per μl) | 1052 (831) | 40 (46) |
| ALT (U/liter) | 38.7 (26.5) | 34.6(29.9) |
| Concomitant treatment | ||
| Hydroxychloroquine | 79 (95.2) | 80 (96.4) |
| Antibiotics | 79 (95.2) | 79 (95.2) |
| Lopinavir/ritonavir | 69 (83.1) | 71 (85.5) |
| LMWH | 82 (98.8) | 82 (98.8) |
| Glucocorticoids | 71(85.5) | 70 (84.3) |
| Primary outcome | 14 (16.9)* | 29 (34.9)* |
| Time to outcome | 19.9 (9.1)** | 13.1 (9.7)** |
*P < 0.01
**P < 0.001